When Britt Meelby Jensen started as CEO at Zealand Pharma in March 2015, she was dubbed "the new biotech queen" by the media. However, the executive was not happy about the title – not because of challenges she experiences as a woman in her everyday life, but because it shows that society still has a long way to go, she says.
"I think it reflects where we are as a society. Men don't often get titles like that – you wouldn't call Lars Fruergaard Jørgensen [CEO of Novo Nordisk, ed.] the 'pharma king'. Unfortunately, I think it demonstrates how there are still few female top executives in Denmark," Meelby Jensen says.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.